Belzutifan cabozantinib combo shows durable anti-tumour effect at phase II for ccRCC

ESMO 2023: Latest in EGFR Ex20ins advanced NSCLC

Adagrasib pembrolizumab combo shows promise for KRASG12C-positive NSCLC

Selpercatinib benefit for advanced, kinase inhibitor-naïve, RET-mutant medullary thyroid cancer

Cost-benefit analysis of new cancer medicines: The difficult choices of governments

Epitope editing enables targeted immunotherapy of acute myeloid leukaemia

Osimertinib plus chemotherapy shows superior results versus osimertinib alone for EGFR-mutated advanced lung cancer

OncoAlert Round Up for September 1-7, 2023

Part 6: Which different PARP inhibitors are available

Part 7: Similarities and Differences

Part 8: How PARP inhibitors are being used now

Part 9: What PARP inhibitors mean for the future and what to look out for